← Leaderboards
Igor S. Lukashevich
University Of Wisconsin Madison
$5,328,598
Attributed
$7,856,278
Total exposure
7
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $868K · FY2005–18$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
Funding mix
By agency
NIH$7,856,278 · 7
By mechanism
R01$6,550,110 · 4
R56$851,962 · 1
R21$399,055 · 1
P51$55,151 · 1
Top collaborators
- Peter M. Pushko6 shared
- Juan C. De La Torre1 shared
- Slobodan Paessler1 shared
Most similar at University Of Wisconsin Madison
Same institution · by research overlap
- Dale E Bjorling$12,288,243
- Matthew J Allen$6,273,243
- Michael T Bailey$5,509,666
- Chien Ho$26,784,666
- Marulasiddappa Suresh$13,249,290
Others in their field
Top investigators on “Vaccines”
- Lawrence Corey · Fred Hutchinson Cancer Center$829,044,908
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$556,540,832
- Bambra Strokes · Ppd Development Lp$526,656,217
- Barton F Haynes · Duke University$515,215,260
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$398,445,678
- Dennis R. Burton · Scripps Research Institute$316,106,418
Research focus
VaccinesCaviaLassa FeverAfricaBaseAnimalsVectorLassa VirusAntigensVirusImmunizationPathogenGenesImmunogenicityDesignRecombinant VirusNonhuman PrimateAffectGlycoproteinsLeadRecombinantsArenavirusBiodefenseNucleoproteins
Grant awards (18)
Reverse Genetics To Forward The Pan-Lassa Fever Vaccine Lead Candidate ML29$851,962
R56 · FY2018 · AI
Development of New Bivalent Cross-Protective Arenaviral Vaccines$727,652
R01 · FY2015 · AI · contact PI
Development of New Bivalent Cross-Protective Arenaviral Vaccines$727,652
R01 · FY2014 · AI · contact PI
Development of New Bivalent Cross-Protective Arenaviral Vaccines$773,368
R01 · FY2013 · AI · contact PI
Development of New Bivalent Cross-Protective Arenaviral Vaccines$822,732
R01 · FY2012 · AI · contact PI
Development of New Bivalent Cross-Protective Arenaviral Vaccines$745,933
R01 · FY2011 · AI · contact PI
Development of New Bivalent Cross-Protective Arenaviral Vaccines$122,074
R01 · FY2011 · AI · contact PI
Recombinant Yellow Fever 17D-Lassa Vaccine$535,411
R01 · FY2008 · AI · contact PI
IMMUNOGENICITY OF RECOMBINANT YF17D-LASSA VACCINE IN COMMON MARMOSETS$55,151
P51 · FY2008 · RR · contact PI
Recombinant Yellow Fever 17D-Lassa Vaccine$374,691
R01 · FY2007 · AI · contact PI
MOP/LAS chimeric vaccine against Lassa fever$194,846
R01 · FY2007 · AI · contact PI
MOP/LAS chimeric vaccine against Lassa fever$187,512
R01 · FY2007 · AI · contact PI
MOP/LAS chimeric vaccine against Lassa fever$382,948
R01 · FY2006 · AI · contact PI
MOP/LAS chimeric vaccine against Lassa fever$381,418
R01 · FY2005 · AI
MOP/LAS chimeric vaccine against Lassa fever$431,489
R01 · FY2004 · AI
Mopeia/Lassa Virus Reassortants as Lassa Fever Vaccines$399,055
R21 · FY2002 · AI
MUCOSAL INFECTION WITH ARENAVIRUS$91,876
R01 · FY2000 · RR
MUCOSAL INFECTION WITH ARENAVIRUS$50,508
R01 · FY2000 · RR